Skip to main content
Top

2009 | OriginalPaper | Hoofdstuk

18 Ziekte van Alzheimer

Auteurs : Ph. Scheltens, W.M. van der Flier, A.M. Rozemuller, Y.A.L. Pijnenburg

Gepubliceerd in: Handboek dementie

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Kernpunten

  • De ziekte van Alzheimer is de meest voorkomende vorm van dementie.
  • De klinische diagnose wordt gesteld op basis van (hetero)anamnese, gedragsobservatie, lichamelijk/neurologisch en cognitief onderzoek, en zo nodig aanvullend beeldvormend en liquoronderzoek.
  • De kenmerkende neuropathologische veranderingen zijn (amyloïd en neuritische) plaques, neurofibrillaire tangles, synapsverlies en geactiveerde microglia.
  • Psychosociale behandeling is ondersteunend en gericht op de zorgbehoefte van de patiënt en diens omgeving. Medicamenteuze behandeling is gericht op het verbeteren/stabiliseren van de cognitieve problemen.
Literatuur
go back to reference Bennett DA, Wilson RS, Schneider JA, et al. Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology 2003;60(12):1909-15. Bennett DA, Wilson RS, Schneider JA, et al. Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology 2003;60(12):1909-15.
go back to reference Bouwman FH, Schoonenboom SN, Flier WM van der, et al. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging. 2007;28(7):1070-4. Bouwman FH, Schoonenboom SN, Flier WM van der, et al. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging. 2007;28(7):1070-4.
go back to reference Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389-404. Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389-404.
go back to reference Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239-59. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239-59.
go back to reference Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. Neurobiol Aging 1997;18:S1–2. Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. Neurobiol Aging 1997;18:S1–2.
go back to reference Flier WM van der, Schoonenboom SN, Pijnenburg YA, et al. The effect of APOE genotype on clinical phenotype in Alzheimer disease. Neurology. 2006;67(3):526-7. Flier WM van der, Schoonenboom SN, Pijnenburg YA, et al. The effect of APOE genotype on clinical phenotype in Alzheimer disease. Neurology. 2006;67(3):526-7.
go back to reference Flier WM van der, Staekenborg S, Pijnenburg YA, et al. Apolipoprotein E genotype influences presence and severity of delusions and aggressive behavior in Alzheimer disease. Dement Geriatr Cogn Disord 2007;23:42-6. Flier WM van der, Staekenborg S, Pijnenburg YA, et al. Apolipoprotein E genotype influences presence and severity of delusions and aggressive behavior in Alzheimer disease. Dement Geriatr Cogn Disord 2007;23:42-6.
go back to reference Hsiung GYR, Sadovnick AD. Genetics and dementia: riskfactors, diagnosis and management. Alzheimers Dement. 2007;3:418-27. Hsiung GYR, Sadovnick AD. Genetics and dementia: riskfactors, diagnosis and management. Alzheimers Dement. 2007;3:418-27.
go back to reference Kivipelto M, Ngandu T, Laatikainen T, et al. Riskscore for prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 2006;5:735-41. Kivipelto M, Ngandu T, Laatikainen T, et al. Riskscore for prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 2006;5:735-41.
go back to reference Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-19. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-19.
go back to reference Kwaliteitsinstituut voor de gezondheidszorg CBO. Richtlijn Diagnostiek en medicamenteuze behandeling van dementie. 2005. www.cbo.nl. Kwaliteitsinstituut voor de gezondheidszorg CBO. Richtlijn Diagnostiek en medicamenteuze behandeling van dementie. 2005. www.cbo.nl.
go back to reference Larner AJ, Doran M. Clinical phenotypic heterogeneity of Alzheimer’s disease associated with mutations of the presenilin-1 gene. J Neurol. 2006;253:139-58. Larner AJ, Doran M. Clinical phenotypic heterogeneity of Alzheimer’s disease associated with mutations of the presenilin-1 gene. J Neurol. 2006;253:139-58.
go back to reference McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34(7):939-44. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34(7):939-44.
go back to reference Patterson C, et al. Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ. 2008;178:548-56. Patterson C, et al. Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ. 2008;178:548-56.
go back to reference Piscopo P, Marcon G, Piras MR et al. A novel PSEN2 mutation associated with a peculiar phenotype. Neurology. 2008;70:1549-54. Piscopo P, Marcon G, Piras MR et al. A novel PSEN2 mutation associated with a peculiar phenotype. Neurology. 2008;70:1549-54.
go back to reference Raina P, Santaguida P, Ismaila A, et al. Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline. Ann Intern Med. 2008;148: 379-97. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline. Ann Intern Med. 2008;148: 379-97.
go back to reference Scheltens P, Fox N, Barkhof F, et al. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol. 2002;1(1):13-21. Scheltens P, Fox N, Barkhof F, et al. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol. 2002;1(1):13-21.
go back to reference Waring SC, Rosenberg RN. Genome-wide association studies in Alzheimer disease. Arch Neurol. 2008;65:329-34. Waring SC, Rosenberg RN. Genome-wide association studies in Alzheimer disease. Arch Neurol. 2008;65:329-34.
Metagegevens
Titel
18 Ziekte van Alzheimer
Auteurs
Ph. Scheltens
W.M. van der Flier
A.M. Rozemuller
Y.A.L. Pijnenburg
Copyright
2009
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-313-8061-9_18